Q3 Earnings Estimate for GH Research Issued By HC Wainwright

Key Points

• HC Wainwright has increased its Q3 2025 earnings per share estimate for GH Research from ($0.22) to ($0.19), maintaining a "Buy" rating with a price target of $40.00.
• The current consensus estimate for GH Research's full-year earnings is ($0.80) per share, while the stock has experienced a recent increase of 3.5%.
• Institutional investors now own 56.90% of GH Research's stock, with notable increases in positions from multiple hedge funds in the recent quarters.

GH Research PLC (NASDAQ:GHRS - Free Report) - Analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of GH Research in a research note issued to investors on Monday, August 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.19) for the quarter, up from their prior estimate of ($0.22). HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research's Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.39) EPS.

GHRS has been the topic of several other research reports. Cantor Fitzgerald started coverage on GH Research in a report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a report on Tuesday, June 24th. Guggenheim reduced their target price on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, GH Research presently has an average rating of "Moderate Buy" and a consensus price target of $32.00.

GH Research Stock Up 3.5%

GHRS stock opened at $12.56 on Thursday. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The stock's fifty day simple moving average is $13.90 and its 200-day simple moving average is $12.10. The stock has a market capitalization of $653.47 million, a price-to-earnings ratio of -16.97 and a beta of 0.98.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GHRS. RA Capital Management L.P. increased its position in shares of GH Research by 3.9% during the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock worth $76,599,000 after acquiring an additional 257,959 shares during the last quarter. Lynx1 Capital Management LP increased its position in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after acquiring an additional 663,100 shares during the last quarter. Cormorant Asset Management LP increased its position in shares of GH Research by 238.8% during the first quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock worth $22,165,000 after acquiring an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of GH Research during the first quarter worth about $8,272,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of GH Research during the first quarter worth about $5,018,000. Institutional investors and hedge funds own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.